Glenshaw, PA, United States of America

Judith A Kantor

USPTO Granted Patents = 18 


 

Average Co-Inventor Count = 2.5

ph-index = 10

Forward Citations = 275(Granted Patents)


Location History:

  • Rockville, MD (US) (1983 - 2022)
  • Glenshaw, PA (US) (2016 - 2024)

Company Filing History:


Years Active: 1983-2025

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: Judith A. Kantor: Innovator in Monoclonal Antibody Research

Introduction

Judith A. Kantor is a prominent inventor based in Glenshaw, Pennsylvania, known for her significant contributions to the field of biomedical research. With a total of 18 patents to her name, she has made remarkable advancements in the development of recombinant monoclonal antibodies, particularly in relation to cancer treatment.

Latest Patents

One of her latest patents focuses on recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers. This invention provides for antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens. It includes nucleic acid sequences encoding the antibody chains and the amino acid sequences corresponding to these nucleic acids. The applications of these antibodies, nucleic acids, and amino acids are crucial for advancing cancer therapies.

Career Highlights

Throughout her career, Judith has worked with notable organizations such as Precision Biologics, Inc. and the National Institutes of Health, a component of the US Department of Health & Human Services. Her work has been instrumental in pushing the boundaries of cancer research and treatment.

Collaborations

Judith has collaborated with esteemed colleagues, including J. Andrew Bristol and Jeffrey Schlom, contributing to a rich environment of innovation and discovery in her field.

Conclusion

Judith A. Kantor's work in monoclonal antibody research exemplifies her dedication to improving cancer treatment through innovative inventions. Her contributions continue to impact the biomedical field significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…